Modern Vaccines Adjuvants Formulation

2-4 May 2018, LUMC – Leiden University Medical Center, Leiden, The Netherlands

  • Increase font size
  • Default font size
  • Decrease font size

Introduction

Join the conversation on Twitter – #MVAF2018

The increasing need for new and improved vaccines and the growing level of sophistication of their associated adjuvantation and delivery systems has major implications for the design, formulation, delivery, manufacturing and quality assessment of modern vaccines and immune interventions in general. MVAF 2018 will be the sixth meeting in this successful series and again will offer an international forum for the discussion of all aspects of vaccine and adjuvant formulation and will focus on:

Innovation in vaccine design, engineering and adjuvantation/delivery technologies
Challenges to manufacturing and the administration/delivery of modern vaccines
Compliance with quality standards and regulatory requirements

MVAF 2018 will then assess the impact of all of the above on the future development/design of vaccines and adjuvants.

MVAF 2018 will be of interest to researchers/contributors from academic programs, industrial, governmental and regulatory groups. Contributions to both the oral and poster programs are encouraged. Potential contributors attention is drawn to the Call For Abstracts in the participation section.

Scientific Advisory Panel

Conference Chairman: Dennis Christensen (SSI, Copenhagen, Denmark)

Adriana Baz Morelli (CSL Ltd, Melbourne, Australia)
Jean Haensler (Sanofi Pasteur, Lyon, France)
Manmohan Singh (Takeda Vaccines Inc., Cambridge, Massachusetts, USA)
Lakshmi Khandke (Pfizer Vaccine Research, Pearl River, New York, USA)
Heather Davis (Pfizer Vaccines Research, Ottawa, Canada)
Chris Fox (IDRI, Seattle, Washington, USA)
Nicolas Collin (University of Lausanne, Lausanne, Switzerland)
Maria Lazaro (SEPPIC, Paris, France)
Ken Ishii (University of Osaka, Osaka, Japan)
Erik Lindblad (Brenntag Biosector, Frederikssund, Denmark)
Gideon Kersten (Intravacc, Bilthoven, The Netherlands)

Conference Scope

The following list of topics is not exhaustive but reflects the variety of subjects that this area of vaccine/adjuvant technology and development encompasses:

Innovative Vaccine Concepts and Designs
Molecular Approaches to Vaccine Design
Vaccine Immunology/Immunogenicity Studies
Vaccine Design, Engineering & Formulation
Modelling Methods
Vaccine/Adjuvant Delivery Issues & Systems
Vaccine/Adjuvant Diversity – Live or Inactivated Virus/Recombinant Protein
Polysaccharide or Peptide (free versus conjugated)
Viral Vectors/DNA Vectors
VLPs & Nanoparticulate Vaccines
Administration Devices/Methods (oral/nasal/transcutaneous/needle-free)

Process & Manufacturing
Protein Stabilization/Virus Stablization/Vaccine Stabilization
Vaccine Preservation Issues – New/Novel Vaccine Preservatives
Vaccine Stability Monitoring Methods

Characterization and quality assessment in compliance with regulatory guidelines
Vaccine/Adjuvant Quality, Purity & Potency/Efficacy & Safety
Safety Evaluation Considerations
Assay Development Aspects
Toxicology Studies
Regulatory Guidelines – National/International for Adjuvanted Vaccines

 

MVAF 2018 Delegates

Login details will be supplied after you have registered for the event.


MVAF 2018 Sponsors

  • CureVac
  • VaxArt
  • Inovio Pharmaceuticals
  • Brenntag
  • hVIVO
  • Seppic
  • DNAvaccine.com
  • Bioaster
  • Intravacc
  • Aldevron
  • EVI
  • Sanofi Pasteur
  • NatureGeneTherapy.com
  • IDRI

MVAF 2018 Downloads

MVAF 2018 Leaflet

MVAF 2018 Mailing List

Name
E-mail Address
What is 3+2-1?